I Tinhofer1, K Jöhrens2, U Keilholz3, A Kaufmann4, A Lehmann5, W Weichert6, A Stenzinger7, C Stromberger8, K Klinghammer9, E-T Becker10, S Dommerich10, K Stölzel10, V M Hofmann10, B Hildebrandt9, L Moser8, J Ervens11, A Böttcher10, A Albers10, R Stabenow12, A Reinecke13, V Budach14, B Hoffmeister11, J D Raguse11. 1. Charité Comprehensive Cancer Center, Working Group for Head and Neck Cancer, Berlin, Germany; Department of Radiooncology and Radiotherapy, Charité University Medicine, Berlin, Germany; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Partner Site Berlin, Germany. Electronic address: ingeborg.tinhofer@charite.de. 2. Charité Comprehensive Cancer Center, Working Group for Head and Neck Cancer, Berlin, Germany; Institute of Pathology, Charité University Medicine, Berlin, Germany. 3. Charité Comprehensive Cancer Center, Working Group for Head and Neck Cancer, Berlin, Germany; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Partner Site Berlin, Germany; Department of Hematology and Medical Oncology, Charité University Medicine, Berlin, Germany. 4. Department of Gynecology, Charité University Medicine, Berlin, Germany. 5. Institute of Pathology, Charité University Medicine, Berlin, Germany. 6. Institute of Pathology, University Hospital Heidelberg and National Center for Tumor Diseases (NCT), Heidelberg, Germany; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany. 7. Institute of Pathology, University Hospital Heidelberg and National Center for Tumor Diseases (NCT), Heidelberg, Germany. 8. Charité Comprehensive Cancer Center, Working Group for Head and Neck Cancer, Berlin, Germany; Department of Radiooncology and Radiotherapy, Charité University Medicine, Berlin, Germany. 9. Charité Comprehensive Cancer Center, Working Group for Head and Neck Cancer, Berlin, Germany; Department of Hematology and Medical Oncology, Charité University Medicine, Berlin, Germany. 10. Charité Comprehensive Cancer Center, Working Group for Head and Neck Cancer, Berlin, Germany; Department of Otorhinolaryngology, Charité University Medicine, Berlin, Germany. 11. Charité Comprehensive Cancer Center, Working Group for Head and Neck Cancer, Berlin, Germany; Department of Oral and Maxillofacial Surgery, Charité University Medicine, Berlin, Germany. 12. Common Tumor Registry of the Federal States of Berlin, Brandenburg, Mecklenburg-Western Pomerania, Saxony-Anhalt, Saxony and Thuringia, Germany. 13. Tumorzentrum Berlin e.V., Berlin, Germany. 14. Charité Comprehensive Cancer Center, Working Group for Head and Neck Cancer, Berlin, Germany; Department of Radiooncology and Radiotherapy, Charité University Medicine, Berlin, Germany; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Partner Site Berlin, Germany.
Abstract
BACKGROUND: Increases in incidence of oropharyngeal squamous cell carcinoma (OPSCC) in countries with falling tobacco use have been attributed to a growing role of human papilloma virus (HPV) in the carcinogenesis. Trends of HPV prevalence in populations with persistently high portions of smokers are poorly characterised. PATIENTS AND METHODS: Registry data from East Germany were used to determine incidence trends between 1998 and 2011. Data from patients treated at the Charité University Medicine Berlin between 2004 and 2013 (cohort 1, N=436) were used for estimation of trends in HPV prevalence, smoking and survival. HPV prevalence was prospectively confirmed in cohort 2 (N=213) comprising all primary HNSCC cases at the Charité in 2013. RESULTS: Between 1998 and 2011 incidence of both OPSCC and non-OPSCC increased. An increase in HPV prevalence (% of HPV+ cases in 2004-2006 versus 2012-2013: 27% versus 59%, P=0.0004) accompanied by a moderate decrease in the portion of current smokers was observed in OPSCC but not in non-OPSCC. The change in disease epidemiology in OPSCC was associated with significant improvement in overall survival. Increased HPV prevalence in OPSCC (48%) compared to non-OPSCC (11%) was confirmed in cohort 2. CONCLUSIONS: Despite clear differences to the United States in terms of tobacco use, the increase in OPSCC incidence in a European population was also mainly attributed to HPV, and the HPV status significantly affected prognosis. For clinical trial design it is important to consider the large group of smokers within HPV-induced OPSCC.
BACKGROUND: Increases in incidence of oropharyngeal squamous cell carcinoma (OPSCC) in countries with falling tobacco use have been attributed to a growing role of human papilloma virus (HPV) in the carcinogenesis. Trends of HPV prevalence in populations with persistently high portions of smokers are poorly characterised. PATIENTS AND METHODS: Registry data from East Germany were used to determine incidence trends between 1998 and 2011. Data from patients treated at the Charité University Medicine Berlin between 2004 and 2013 (cohort 1, N=436) were used for estimation of trends in HPV prevalence, smoking and survival. HPV prevalence was prospectively confirmed in cohort 2 (N=213) comprising all primary HNSCC cases at the Charité in 2013. RESULTS: Between 1998 and 2011 incidence of both OPSCC and non-OPSCC increased. An increase in HPV prevalence (% of HPV+ cases in 2004-2006 versus 2012-2013: 27% versus 59%, P=0.0004) accompanied by a moderate decrease in the portion of current smokers was observed in OPSCC but not in non-OPSCC. The change in disease epidemiology in OPSCC was associated with significant improvement in overall survival. Increased HPV prevalence in OPSCC (48%) compared to non-OPSCC (11%) was confirmed in cohort 2. CONCLUSIONS: Despite clear differences to the United States in terms of tobacco use, the increase in OPSCC incidence in a European population was also mainly attributed to HPV, and the HPV status significantly affected prognosis. For clinical trial design it is important to consider the large group of smokers within HPV-induced OPSCC.
Authors: M Reuschenbach; S Wagner; N Würdemann; S J Sharma; E-S Prigge; M Sauer; A Wittig; C Wittekindt; M von Knebel Doeberitz; J P Klussmann Journal: HNO Date: 2016-07 Impact factor: 1.284
Authors: Andreas E Albers; Regina Grabow; Xu Qian; Masen D Jumah; Veit M Hofmann; Alexander Krannich; Gabriele Pecher Journal: Mol Clin Oncol Date: 2017-06-01
Authors: Moonef Alotaibi; Valeria Valova; Toni HÄnsel; Carmen Stromberger; Grzegorz Kofla; Heidi Olze; Iris Piwonski; Andreas Albers; Sebastian Ochsenreither; Annekatrin Coordes Journal: In Vivo Date: 2021 Mar-Apr Impact factor: 2.155
Authors: Annekatrin Coordes; Klaus Lenz; Xu Qian; Minoo Lenarz; Andreas M Kaufmann; Andreas E Albers Journal: Eur Arch Otorhinolaryngol Date: 2015-07-31 Impact factor: 2.503